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Background: It is a commonly perceived perception that low-glycaemic index (GI) foods 
keep you feeling fuller for longer due to prolonged postprandial glycaemia (PPG). Thus, it is 
thought that low-GI foods could promote weight loss. However, the published findings on the 
relationship between PPG and satiety are inconclusive. Inconsistency in results could be 
attributable to factors in food other than the food’s glycaemic-inducing properties. For 
example, foods chosen on the basis of GI may also differ in factors such as palatability, 
macro- and micronutrient content, fibre and energy.  
Objective: To determine the effect of PPG on satiety using sucrose (GI= 65) and 
isomaltulose (PalatinoseTM) (GI= 32) sweetened beverages. Sucrose and isomaltulose are both 
disaccharides comprising the monosaccharides glucose and fructose; both sugars are fully 
digested and absorbed; the difference between them being the glycosidic bond that is digested 
more rapidly for sucrose than it is for isomaltulose. 
Design: Double-blinded, randomized controlled crossover trial, in which 77 participants were 
recruited to measure satiety outcomes, 12 of who volunteered for blood glucose 
measurements to determine glycaemic response.  
Methods: Twelve volunteers were recruited for blood glucose measurements at baseline, 30, 
60, 90, 120, 150, and 180-minutes after consumption of a sucrose or isomaltulose sweetened 
beverage, two weeks apart. Blood samples were analysed for blood glucose and insulin 
concentrations. The full 77 participants were randomized to receive one of each beverage, two 
weeks apart. Satiety was measured via visual analogue scales (VASs) at the same time points 
as the blood glucose measurements. VAS questions consisted of; “How hungry do you feel?”; 
“How satisfied do you feel?”; “How full do you feel?”; And “how much do you think you can 
eat?”.  Weighed diet records were kept from 5:00pm (180-minutes after beverage 
consumption) until 12:00am, and were used to compare subsequent energy and macronutrient 
intake. 
	 	 	iv	
Results: Glycaemic and insulinaemic response, measured by incremental area under the curve 
(iAUC), differed significantly between the sucrose and isomaltulose beverages. Mean blood 
glucose concentrations differed by 44mmol/L (95% CI: -70, -18; P= 0.003) and mean blood 
insulin concentrations differed by 1883µIU/L (95% CI: -2846, 921; P= 0.001). VAS 
questions, measured by area under the cure (AUC), showed no difference in hunger (P= 
0.699), satisfaction (P= 0.924), fullness (P= 0.780) or prospective food intake (P= 0.341), 
between the test beverages. No significant difference in subsequent energy (95% CI: -845, 
267; P= 0.306), fat (95% CI: -13.3, 0.2; P= 0.056), protein (95% CI: -8.8, 4.3; P= 0.498) or 
carbohydrate intake (95% CI: -17.2, 20.5; P= 0.864) was found between the beverages.  
Conclusion: There was no difference in measures of satiety following ingestion of sucrose 
and isomaltulose sweetened beverages despite differences in PPG. These findings indicate 
that at the differences in glycemic responses attained in this study, satiety is independent of 
glycaemia per se. Any differences found between foods chosen on the basis of GI could be 
attributable to food properties other than the glycaemic-inducing potential of the food.  
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A major dietary change seen in recent decades is the shift from high quality 
carbohydrates to fibre depleted processed carbohydrates, coincident with the rising rates 
of obesity, type 2 diabetes mellitus and coronary heart disease (CHD) (1). The relevance 
of carbohydrates and postprandial glycaemia (PPG) to metabolic disease risk has been 
debated since the first glycaemic index (GI) publication in 1981 (1). Although evidence is 
conflicting, the Glycaemic Index Foundation claims that low-GI keeps you feeling fuller 
for longer (2). The suggestion that glycaemic responses elicited by carbohydrate 
containing foods may be causal to the rising rates of metabolic diseases (1), requires 
attention to be paid to the impact of PPG on satiety.   
 GI was introduced to determine the effect of different carbohydrate containing 
foods on PPG (3). Foods with a low-GI are characterised as releasing glucose into the 
blood at a slow steady rate, whilst foods with a high-GI are characterised as causing a 
rapid spike in blood glucose and a greater overall glycaemic response (4). The difference 
in glycaemic response is thought to be attributed to the rate at which carbohydrates are 
digested and absorbed, with some low-GI foods thought to have the more favourable 
glycaemic impact on health and disease parameters (5).  
 Low glycaemic foods have been shown to enhance satiety when compared to high 
glycaemic foods (4). It was originally thought that blood glucose concentrations regulated 
food intake, known as the glucostatic theory (6). This theory suggests that increased 
blood glucose concentrations promote satiety, whilst low blood glucose concentrations 
lead to increased feelings of hunger (6). However, evidence of a low glycaemic response 
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correlating to higher satiation is conflicting and more recent evidence suggests blood 
glucose concentrations are not the primary determinant of satiety (7).The inconsistencies 
between studies may be explained by factors other than the glycaemic effect such as: 
cooking and processing methods, the presence of fibre, and the presence of other 
macronutrients (4). The differences could also be attributed to variable study designs and 
methods used to measure satiety, such as visual analogue scales (VASs) or weighed diet 
records (8).  
 The purpose of this study was to compare the effect of a sucrose (medium-GI) and 
a sucrose alternative (low-GI) beverage on satiety. The sucrose alternative used was 
isomaltulose. Although a fully digestible carbohydrate, it is digested at a slower rate than 
sucrose due to its more stable alpha-1,6 glycosidic bond, compared with sucrose’s alpha-
1,4 linkage (9). This data will be novel because all properties of the beverages will be 
controlled for, leaving only the difference in digestion as an explanatory factor if 
outcomes differ. 
 Therefore, this double-blinded, randomised controlled crossover trial was 
designed to assess the satiating potential of the two sugars, in the absence of confounding 
factors. The results can be used to provide further evidenced based recommendations on 
low glycaemic sucrose alternatives, in relation to reducing food intake for weight 










The purpose of this literature review was to investigate the effect of postprandial 
glycaemia (PPG) on satiety.   
Specifically, this review focuses on:  
• Providing an overview of glycaemic response. 
• Defining glycaemic index (GI) and glycaemic load (GL). 
• Discussing GI and GL in terms of weight management.     
• How glycaemic response may affect satiety, including a description of the 
glucostatic theory. 
• Comparing the properties of isomaltulose to sucrose.  
• Recognising gaps in the current literature around measuring the effect of 
glycaemic response on satiety, in isolation of confounding meal components, to 
develop a rationale for this study.  
3.2 Literature	review	methodology	
 
Literature was sourced from the following online databases: Medline, Scopus, Science 
Direct and Pubmed. Search key words included: ‘glycaemic response, ‘glycaemia’, 
‘glycaemic index’, ‘glycaemic load’, ‘isomaltulose’, ‘glucostatic theory’, ‘glycaemic 
response and satiety’, ‘glycaemic index and satiety’, ‘isomaltulose and satiety’. Further 
references in articles found from these online searches were used. Articles from 1956 to 





Glycaemic response or PPG refers to the change in blood glucose levels after consuming 
a carbohydrate containing meal (10). Glucose concentrations begin to rise approximately 
ten-minutes after the start of a meal due to the absorption of carbohydrates (10). The rate 
at which this occurs depends on the amount and type of carbohydrate consumed (11). In a 
healthy individual, blood glucose levels typically rise no higher than 7.8mmol/L in 
response to a meal and return to pre-meal concentrations within two to three hours (12).  
However, glycaemic response can vary widely between individuals (13), due to a host of 
factors. It has been found that those from South Asia elicit a glycaemic response that is 
two to three times larger than Caucasians, indicating considerable metabolic differences 
between ethnicities (14). It has also been found that differing dentition, chewing rates and 
eating behaviour between individuals results in different particle sizes which influences 
the magnitude and pattern of the glycaemic response (15).  
 
Additionally, approximately 150 million people worldwide have Diabetes Mellitus with 
this number expected to double by 2025 (16), signifying a large proportion of the 
population with insulin resistance. Insulin resistance results in a higher glycaemic 
response due to glucose accumulating in the blood, unable to enter body cells (17), 




The GI concept was introduced in the early 1980’s as a ranking system for carbohydrates 
based on their blood glucose raising ability (18, 19). GI is defined as the incremental area 
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under the glycaemic response curve elicited by a test food containing 50g of available 
carbohydrate, expressed as a percentage of the area under the curve (AUC) elicited by 
50g of glucose from a reference food (or mean of two to three glucose references), in the 
same subject (19). The mean GI value of the set number of participants (usually 10 or 12) 
is used to determine the overall GI value for that food (20). Carbohydrate based foods 
have been classified into three categories according to their GI to help predict glycaemic 
response. Foods with a low-GI are defined as <55, intermediate-GI as 55 – 70 and a high-
GI as >70 (21).  
3.3.2 Glycaemic	load	(GL)	
 
Both the type and quantity of carbohydrate consumed influence the glycaemic response 
(3). However, GI only takes into account the type of carbohydrate and is based on a fixed 
amount of available carbohydrate (11). In order to improve the predictability of 
glycaemic response, GL was introduced to include the amount of available carbohydrate 
consumed (GL = GI X available carbohydrate (g) / 100) (4). Thus, GL can assess the total 
glycaemic effect of the diet (11). 
3.3.3 Glycaemic	response	and	weight	management		
 
Diets that elicit a low glycaemic response have been suggested as a means of improving 
chronic health conditions such as diabetes mellitus, obesity and risk of CHD (22). 
However, literature is inconsistent and it appears the health benefits of a low-GI diet are 
more prominent in overweight and/or insulin resistant individuals, than healthy 




From observational data, when ranked into percentiles of GI and GL, it has been found 
that GI or GL are unrelated to BMI in the populations studied (22-25). Data from the 
European Prospective Investigation into Cancer and Nutrition showed no interaction with 
BMI status or other anthropometric measurements in relation to quintiles of GI or GL 
intake (25). In an observational study conducted in 646 elderly men, those with a higher 
dietary intake of GI had a lower BMI, although the difference was only minimal with a 
1.1kg/m2 difference between the low and high tertile of energy-adjusted GI intake (26). 
Thus, data from observational studies do not support the contention that low glycaemic 
diets are beneficial for weight loss.  
 
In a review that analysed 13 long-term human intervention studies (>6 days) that used 
low or high glycaemic treatments, a greater weight loss on a low glycaemic diet was seen 
in two studies, greater weight loss on a high glycaemic diet was seen in one, and no 
difference was recorded in ten (27). The average weight loss across these 13 studies was 
0.2kg on the low glycaemic diet and 0.7kg on the high glycaemic diet (27). Thus, these 
results provide no evidence that low glycaemic diets promote weight loss any more than 
high glycaemic diets. The CARMEN multicentre trial that was conducted in 398 
moderately obese adults, found that six-months ad libitum intake of low-fat diets rich in 
either low or high glycaemic carbohydrates, reduced body weight by 1.6-2.4kg compared 
with the normal-fat control diet (28). Study findings indicate no significant difference 
between the low and high glycaemic carbohydrate diets. Therefore, in this particular 
study a reduced fat diet rich in carbohydrate was beneficial for weight loss regardless of 





Satiation determines meal size as it is the mechanism that leads to meal cessation (21). In 
contrast, satiety impacts meal frequency by supressing hunger for a period of time (21). 
In order to measure these subjective feelings of appetite, visual analogue scales (VASs) 
are often used (29). VASs are composed of lines with words anchored at each end 
describing opposing statements, and participants allocate a mark on the continuum to 
describe their feelings of: hunger, satisfaction, fullness, and prospective food 
consumption (29). Satiety can also be measured by food intake at the next meal via 
weighed diet records.  
 
A systematic review found evidence from short-term studies (<1 day) that low glycaemic 
foods have a higher satiating effect than high glycaemic foods (21). However, 
confounding may have been an issue because studies for this systematic review were 
selected for analysis if the energy and macronutrient composition of the test meals were 
similar. However, this did not guarantee there were no differences in fat and protein 
content of the test foods, components that could have an effect on satiety independent of 
GI (21). Furthermore, selection criteria did not include fibre content or palatability of the 
test foods, which both influence satiety independent of the GI (21). Therefore, whilst 12 
out of the 18 short-term studies reviewed showed evidence of an increase in satiety with 
low glycaemic foods, this connection is actually very weak (21). Due to the increasing 
presence of confounding factors in longer term studies (>1 day), the systematic review 
did not make any conclusions on low glycaemic diets and satieogenic health benefits in 




In another review, a subset of studies that investigated GI and satiety short-term (<1 day) 
whilst controlling for all test meal components, were examined independently of the 
poorer controlled studies that had differences in test diets such as energy density and 
palatability (8). These studies found no correlation between GI and satiety using VASs. 
However, all studies that also used weighed diet records to measure subsequent energy 
intake found that consumption of high glycaemic foods promoted higher energy intake at 
the next meal when compared with low glycaemic foods (8). These results convey the 
importance of using both VASs and weighed diet records to determine satiety.  
An acute feeding study fed 1000kJ isoenergetic portions of food to fasting subjects, after 
which a standard meal was provided and ad libitum food intake was recorded (30). As 
most of the carbohydrate foods used in the study were less energy dense than the other 
servings of food, participants had to eat a larger volume of these foods to create 
isoenergetic portions (30) It was found that food volume and thus energy density was a 
stronger predictor of individual satiety than the foods glycaemic impact. Furthermore, 
there was no significant relationship found between satiety and blood glucose 
concentrations (30), as the glucostatic theory suggests (6). 
 
Fewer long-term studies have been conducted comparing low and high glycaemic diets. 
However, in many longer term studies the correlation between low glycaemic foods and 
an enhanced feeling of fullness has not been found. It is important to note that isolating 
the effect of low glycaemic foods long-term can be difficult due to numerous 
confounding factors such as: meal duration, macronutrient composition, energy density, 
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textural properties, fibre content and palatability (30-32). 
An 8-day randomized controlled trial found that consumption of only low or high-GI 
foods (served alone or in mixed meals with identical macronutrient composition), did not 
elicit a significantly different glycaemic response (31). This may have been attributed to 
no set meal duration, as slower rates of eating moderates glycaemic and insulinaemic 
responses (31). Subsequently, there were no significant differences in appetite or energy 
intake (31). A similar study investigating the effect of a low-fat, high-carbohydrate diet, 
with either low or high-GI carbohydrates (with all other dietary components being equal) 
over 10-weeks had comparable results (32). This parallel, randomized controlled trial 
found no significant difference in energy intake or changes in body weight between the 
two diets (32). Additionally, diaries filled out on a daily basis by the participants showed 
no difference in ratings of hunger or fullness (32). These results support the notion that 
carbohydrate content is a greater determinant of satiety than GI itself (30, 32). 
The current available literature is equivocal regarding the predictive power of the GI of 
foods and subsequent satiation. While there is some evidence from short-term studies that 
show low glycaemic foods have higher satieogenic properties than high glycaemic-foods, 
the current long-term studies do not support this hypothesis.  
3.4.1 The	glucostatic	theory		
 
Jean Mayer proposed the glucostatic theory in 1953 (33). The proposition was that low 
blood glucose concentrations trigger hunger and the onset of feeding, whilst high blood 
glucose signals satiety and prevents further feeding (34). This short term energy 
regulation mechanism relies on the concept that changes in blood glucose concentrations 
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are detected by glucoreceptors, possibly in the hypothalamic centres (6). Lower and 
slower glucose and insulin responses are believed to promote satiety, whilst large 
increases in blood glucose and insulin concentrations may result in a hypoglycaemic 
undershoot, which leads to an increase in hunger (34). However, evidence that blood 
glucose is the primary determinant of satiety and food intake in humans is inconsistent 
(7).  
 
A study conducted to determine if changes in hunger were related to changes in blood 
glucose concentrations, found that hunger increased after transient declines in blood 
glucose, and no change in hunger occurred when blood glucose concentrations were 
stable (35). A review of multiple studies suggests that a trend toward hypoglycaemia 
might induce excess energy intake, weight gain and impaired glucose tolerance, in 
agreement with the glucostatic theory (36). Thus, a low-GI meal is predicted to result in a 
more stable blood glucose response, inducing satiety and reducing energy intake.  
 
However, a number of studies have been unable to demonstrate a relationship between 
blood glucose concentrations and appetite. A study that tested the effect of blood glucose 
levels on food intake and appetite, conducted food consumption tests three times per 
week for three weeks on nine healthy adult males (37). These participants were given a 
fixed breakfast at 7.30am, and at 11.30am the test treatments were administered (different 
concentrations of intravenous and intragastric glucose) (37). At 12.00pm the subjects 
were provided a test meal which they were permitted to consume ad libitum and the 
amounts of all food and macronutrients were measured (37). The results of this study 
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showed that although the test treatments resulted in three distinct blood glucose 
concentrations, no significant difference was found in terms of total caloric intake, total 
macronutrients, or feelings of appetite (37). The use of intravenous and intragastric 
administration of glucose removes confounding factors, such as palatability, 
gastrointestinal feelings and the presence of other nutrients, making this a strong study 
that does not support the glucostatic theory.   
 
There are a number of other possible mechanisms that indicate an increase in blood 
glucose is not the primary determinant of satiety following carbohydrate consumption. In 
studies measuring blood glucose concentrations and satiety using different meals, the 
satiety mechanism may instead be related to the differing macronutrient content, as 
protein is considered more satiating than carbohydrate and carbohydrate more satiating 
than fat (7). Furthermore, foods that delay gastric emptying, such as fat, would be 
expected to slow the absorption of food, subsequently delaying the return of hunger (38), 
(39). Gut hormones with the potential to influence satiety are released in response to the 
presence of food in the small intestine, the quantity of hormones released is dictated by 
the length of interaction of the carbohydrates in the intestinal tract (7). A longer 
interaction would be seen with low glycaemic carbohydrates, thus providing yet another 
mechanism of promoting satiety that does not involve the subsequent change in blood 
glucose concentrations.   
3.5 Isomaltulose	(Palatinose)	
 
Isomaltulose (also known by the tradename PalatinoseTM), like sucrose, is a disaccharide 
consisting of the monosaccharides glucose and fructose connected via a glycosidic bond 
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(40) (Figure 3.1). In contrast to sucrose which has an alpha-1,2 glycosidic bond, 







Figure 3.1: The chemical structure of isomaltulose (40). 
Commercial isomaltulose is formed by using glycosyltransferase, which converts the 
alpha-1,2 bond of sucrose into the alpha-1,6 bond of isomaltulose (41) (Figure 3.2).  The 
commercial production of isomaltulose has lead to isomaltulose being used as a sugar in 
Japan and other Asian countries for more than two decades (9).  Although not widely 
used yet, approval for isomaltulose as a novel food was agreed upon in New Zealand and 
Australia in 2007 (40). This decision was based on several toxicity studies showing that 
administration of large doses of isomaltulose did not result in any adverse effects (42), 
and the gastrointestinal tolerance being comparable to that of sucrose (43). Additionally, 
it is thought that isomaltulose can provide health benefits, particularly for those with 









Figure 3.2: Isomaltulose enzymatic rearrangement (41). 
Isomaltulose is approximately half as sweet as sucrose and is naturally found in very low 
levels in sugar cane juice and honey (40). Its caloric value is 16.7 kJ/g (4kcal/g), the same 
as that of sucrose (44). The difference is found in the rate at which the two sugars are 
digested. A three-hour trial observing the glucose and insulin response after consuming a 
50g portion of isomaltulose or sucrose found that isomaltulose produced the lowest blood 
glucose and insulin response, which was more than 50% lower when compared with 
sucrose (9). A similar study found comparable results when tested on overweight 
individuals (45). This study also discovered that with lower glucose and insulin 
responses, postprandial fat oxidation rates were higher, thus having the potential to 
prevent body weight gain and insulin resistance (45).  
3.5.1 Digestion	and	absorption	of	isomaltulose	
 
Isomaltulose is completely hydrolyzed and absorbed in the small intestine (unlike sugar 
alcohols xylitol or sorbitol), although at a slower rate than sucrose (41, 46). Thus, blood 
glucose and insulin concentrations rise slower and reach a lower peak than after sucrose 
consumption (42). This slower rise in blood glucose concentrations has been found in 
both healthy and diabetic individuals (42). 
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Ileostomy work has been conducted to confirm that isomaltulose is completely digestible. 
Ten healthy subjects with an ileostomy participated in the study and consumed a test 
meal containing 50g of isomaltulose on two separate days (9). One test meal was a 
500mL beverage and the other was a 250mL beverage with two biscuits, each containing 
25g of isomaltulose (9). After collecting and examining the ileostomy bag contents, it 
was found that digestibility and absorption of the isomaltulose was virtually complete for 
both test meals, irrespective of the food matrix (9).  
During digestion isomaltulose undergoes hydrolysis of its alpha-1,6 glycosidic bond by 
the sucrase-isomaltase complex (42). This hydrolysis is slower in isomaltulose than 
sucrose and occurs along the entire small intestine, unlike more quickly absorbed sugars 
where absorption only takes place in the upper parts of the small intestine (46). The 
maximal velocity value for the hydrolysis of isomaltulose is only about 26%- 45% of that 
of sucrose’s, due to its more stable alpha-1,6 linkage (43). The slower hydrolysis of 
isomaltulose is evident when observing the blood glucose and insulin responses of the 
two sugars (9, 41-43, 45).   
3.5.2 Isomaltulose	and	satiety		
 
In a Japanese study, rats were sustained on distilled water concentrated with 30% 
isomaltulose or sucrose and subsequent energy intakes were measured on four 
consecutive days (47). The food and total energy intakes during 24-hours were 
significantly decreased in the isomaltulose group compared with the sucrose (47). The 
authors have suggested that this may be due to the isomaltulose group having lower 
gastric emptying rates and significantly lower blood glucose and insulin concentrations 
than the sucrose group, suggesting that isomaltulose may be beneficial for appetite 
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control (47). However, only eight rats were used making this a small study with little 
statistical power, and whether or not these findings are relevant to humans is unknown.    
There appears to be a number of benefits of using isomaltulose as a sugar alternative, 
such as a slower rate of digestion resulting in blunted postprandial glucose and insulin 
responses (41), and an enhanced postprandial fat oxidation rate. The more stable alpha-
1,6 bond cannot be broken down by most mouth bacteria and therefore acids that are 
damaging to the teeth are not produced, making isomaltulose a more tooth friendly 
alternative to sucrose (46). Additionally, it is classified as a low-GI carbohydrate (GI = 
32) (9), proven to improve glycaemic control and blood lipid profiles when compared to 
high-GI carbohydrates (44). However, there appears to be a gap in the literature that 
focuses on the satiating properties of isomaltulose compared to sucrose in humans.  
3.6 Conclusion	and	rationale	for	research		
 
Both obesity and diabetes mellitus have reached epidemic proportions, making these 
metabolic diseases the leading cause of death and disabilities around the world (48). 
These rising rates have paralleled the shift from traditional diets to highly processed 
westernised diets, which are rich in high glycaemic carbohydrates (1). A number of short-
term studies suggest that high glycaemic foods are less satiating than low glycaemic 
foods, which may explain this rise in metabolic disease rates. However, the evidence is 
inconsistent, likely due to confounding making it difficult to isolate any effect of 




Therefore, the current study was conducted to investigate the impact of PPG on satiety by 
using a sucrose (medium-GI) and an isomaltulose (low-GI) beverage, to control for all 
factors, isolating any effect to a difference in glycaemic response. Our double-blind, 
randomised controlled trial will be novel as the satiation of isomaltulose compared to 
sucrose has not been investigated in humans before. Furthermore, satiety will be 
measured via both VASs and weighed diet records to provide both subjective and 
objective data. If the claim that low-GI keeps you fuller for longer is supported by the 
current study (2), isomaltulose used in sugar sweetened beverages could provide a means 
of reducing excess energy intake, despite containing the same energy as sucrose.  In turn, 









The aim of this study was to measure the effects of postprandial glycaemia (PPG) on 
satiety, using sucrose and isomaltulose sweetened beverages.  
The objectives of this study are:  
• To develop two isoenergetic beverages containing either sucrose or isomaltulose 
that are identical in taste and appearance.  
• To measure the glycaemic response of the two beverages via finger-prick 
capillary blood samples. 
• To ascertain whether a low-glycaemic index (GI) beverage makes you feel fuller 
for longer by measuring satiety via visual analogue scales (VASs). 
• To ascertain whether a low-GI beverage provides sustained satiety by measuring 






This study was a double-blinded randomised controlled crossover trial, which ran for 
four-weeks at the Department of Human Nutrition, University of Otago, Dunedin, New 
Zealand in March 2018. The main experiment involved participants ingesting two 
beverages sweetened with different sugars in randomised order, two-weeks apart, and 
measuring satiety outcomes. In preparation for the main experiment, sensory testing was 
carried out by six volunteers in order to match the sweetness of the two beverages; and 
blood glucose testing was carried out by twelve volunteers to quantify differences in the 
glycaemic responses to the two test beverages. 
5.1 Ethics		
 
The study was approved by the Human Ethics Committee of the University of Otago in 
October 2017 (ethics committee number 17/011) (Appendix A). The trial was registered 
with the Australian New Zealand Clinical Trial Registery (ACTRN12618000901202) 
(Appendix B) All subjects gave written informed consent before entering the study 




Seventy-seven people were invited to participate from a 300-level undergraduate Human 
Nutrition class from the University of Otago via class presentation. Twelve of these 
participants volunteered for blood sampling to measure glycaemic	response. Prior to 
these trials six volunteers not involved in the study were recruited for sensory testing of 





Inclusion criteria were all HUNT 311 students aged between 18-60 years old at the 
University of Otago. Participants were not eligible if they had diabetes or an intolerance 
to the sweeteners being used. The Joint Expert Committee on Food Additives confirms 
that sucralose is safe for general food use and an acceptable daily intake of 0.15mg/kg 
body weight has been established (49). Food Standards Australia New Zealand accepted 
isomaltulose as a novel food in 2007, declaring it poses no public health safety concern to 
the majority of consumers (40).  
5.2.3 Randomisation		
 
Randomisation of the beverage the participants received each week was computer 
generated using Microsoft® Excel® for Mac (Microsoft Corporation 2015TM, United 
States of America) by a staff member not involved in the study (Figure 5.1). Once 
prepared, the two beverages were stored in different refrigerators and were distributed by 
two members of staff not involved in the study. To ensure double-blinding, the type of 










Figure 5.1: Representation of study design and order of test beverages participants were 
randomised too.  
5.3 Study	Design		
 
The study was designed as a double-blinded randomized controlled trial, in which 77 
participants were recruited to consume a single 500mL beverage two weeks apart, one of 
which contained 50g of sucrose and one which contained 50g of isomaltulose and 0.035g 
of sucralose. Satiety was measured via visual analogue scale (VAS) questionnaires 
(Appendix D) and weighed diet records. Glycaemic response was measured via finger-
prick capillary blood samples on twelve volunteers from the total study participants, after 
consumption of each of the beverages, two weeks apart. The laboratory timelines are 
presented in Figures 5.2 and 5.3. 
 
To ensure double-blinding, the drinks had the same volume and appearance and were 





Figure 5.2: Timeline of glycaemic laboratory testing sessions (week 1 and week 3).  
 
Figure 5.3: Timeline of satiety laboratory testing sessions (week 2 and week 4).  
5.4 Test	beverages		
 
The beverages were made up in 500mL bottles of Pure New Zealand sparkling water. 
Fifty grams of sucrose (caster sugar, Smart Choice; New Zealand) or isomaltulose 
(unflavoured Palatinose®, Myprotein; United Kingdom), were measured on calibrated 
electronic scales (Sartorius, model 1702, Germany) accurate to one hundredth of a gram. 
Fifty grams of sucrose or isomaltulose were used as that is how much sugar is in a 
standard 500mL sugar sweetened beverage (50), making it representative of a beverage 







The composition of each test beverage is shown in Table 5.1. As isomaltulose is 
approximately half as sweet as sucrose (40), the sweetener sucralose (98% sucralose 
powder, J66736, lot:T21D050 Alfa Aesar; China) was used in the artificially sweetened 
beverages. The amount of 0.035g was decided upon based on trial and error and loosely 
following the sweetening compositions comprising sucralose and isomaltulose patent as a 
guide (51). To ensure the beverages were both palatable and indistinguishable from each 
other they were served chilled, and lemon flavouring (Lemon 59223, lot:1002802470, 
Invita NZ Ltd; New Zealand) and carbonated water were used. Both beverages appeared 
and tasted identical.  
 







Sucrose Isomaltulose Sucralose 
Sucrose 0.05mL 50.00g 0g 0g 
 
Isomaltulose 0.05mL 0g 50.00g 0.035g 
 
Abbreviations: mL= millilitre, g= gram.  
5.4.2 Preparation	of	test	beverages		
 
All food safety principles applicable were adhered to in the preparation of these 
beverages (52). This included ensuring a hygienic workplace with clean benches, 
utensils, equipment and washing and drying hands regularly (52). The sucrose and 
isomaltulose beverages were made up in 500mL bottles of Pure New Zealand sparkling 
water. Eighty millilitres and 85mLs of the water were measured in volumetric beakers 
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and removed from the bottles which sucrose and isomaltulose were going to be added 
too, respectively. This is due to isomaltulose expanding more, thus taking up more space 
in the bottle. Fifty grams of sucrose or isomaltulose were measured on calibrated 
electronic scales in plastic containers the day before the laboratory. These containers 
were sealed and placed on allocated trays overnight.  
 
Beverages were prepared three hours before commencement of the laboratories to ensure 
they were chilled upon consumption, by two Master of Dietetics (MDiet) candidates and 
a laboratory technician. The sugars were added to volumetric beakers and filtered boiling 
water was added up to 80mL. The mixture was stirred thoroughly to dissolve the sugar. 
The solutions were then put back into the corresponding bottles and 50uL of lemon 
flavouring was pipetted into all bottles using a P100 pipette (20-100uL, Gilson; France). 
Three and a half grams of sucralose was measured on the calibrated electronic scales and 
dissolved in 100mL of boiling water. One millilitre of this solution was pipetted into the 
isomaltulose beverages using a P1000 pipette (200-1000uL Gilson; France), as each 
beverage required 0.035g of sucralose. The bottle lids were screwed back on tightly, 
inverted four times and put in the refrigerator before consumption. The beverages were 
prepared on the morning of the laboratories to maintain carbonation.  
5.5 Sensory	testing	
 
A triangle sensory test was conducted prior to the study at 11:00am on the 21st February 
2018 at the Sensory Science Research Centre laboratory, University of Otago. During a 
triangle sensory test, a panellist is blinded and presented with one different and two alike 
samples of a product to determine if there is a noticeable difference between them (53). 
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Six participants not involved in the study were recruited to be panellists to test the 
similarity of the two beverages.  
 
The beverages being tested were prepared the morning of the sensory testing, using the 
same procedure that would be used to prepare the beverages for all laboratories. Ten 
millilitres of these beverages were measured and poured into plastic containers, which 
were then labelled with a computer-generated number to identify what beverage was in 
that container. Each participant received a set of three 10mL drinks, four times. The six 
possible order combinations were randomised across panellists and they were instructed 
to test the samples from left to right, cleansing the palate with water between each 
sample. The participants were asked to select which of the three samples was different 
via a computer questionnaire. The participants were unable to distinguish a difference in 
the test beverages. 
5.6 Glycaemic	response	laboratories			
 
Glycaemic response and satiety was measured the first and third week of March on the 
twelve recruited volunteers at the University of Otago Mellor Laboratories. Volunteers 
were asked to fast for two hours prior to the laboratory, and arrive at the laboratory at 
12:00pm to consume their lunch. For standardisation purposes participants were provided 
eight pieces of sushi purchased from WASABI, the University of Otago’s sushi shop. 
Each participant chose a filling which remained the same for both laboratories. The sushi 
was kept refrigerated until being served at 12:00pm. Participants were advised to eat all 
eight pieces of sushi and were provided a 250mL cup of water which they were free to 
refill. After consumption of their meal they were free to leave the laboratory with 
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instruction not to eat or drink (except for water) or undertake strenuous exercise, and 
were asked to return to the laboratory at 1:45pm.  
 
Baseline blood glucose measurements started at 1:50pm and were finished by 2:00pm. At 
2:00pm (baseline) the first VAS questionnaire was completed, after which they were 
asked to consume their beverage within ten-minutes.  
After consumption of the beverage the VAS and blood glucose concentration 
measurements were taken at: 30, 60, 90, 120, 150 and 180-minutes. Participants were 
seated apart from toilet visits until 5:00pm when the laboratory finished.  
5.6.1 Blood	sample	collection		
 
In preparation for the blood collection the participants were given heat packs to 
encourage blood flow to their fingers. The finger being pricked was sanitised using an 
alcohol wipe (Webcol Alcohol Prep, Covidien, United States of America) and gently 
massaged to further encourage blood flow to the finger tips. The chosen finger was then 
pricked off centre, with a 1.5mm X 2.0mm disposable lancet (Contact-Activated Lancet, 
BD Microtainer, United States of America) and further massaged to coax the blood out. 
The first drop of blood was wiped off using a non-woven swab (Multisorb, BSN medical 
limited, United Kingdom). The next 500µL of blood was collected in a microtainer 
containing anti-coagulant (BD Microtainer® Tube with BD Microgard™ Closure. 
K2EDTA anticoagulant additive, 250-500µL fill volume, code number 365975; United 
States of America), which was labelled with the participant’s name and time of 
collection. These microtainers were inverted eight times to ensure the anticoagulant was 
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mixed with the blood. Pricked fingers were then cleaned and plastered (BSN Medical, 
United Kingdom).  
 
The finger-prick procedure was standardised, with the trained assistants taking blood 
from the same participants at the same time, for both blood taking occasions.  
5.6.2 Plasma	analysis		
 
To separate the plasma from the red blood cells, the samples were centrifuged at 2500 xG 
for ten-minutes at room temperature. The plasma was then transferred to a Hitachi cup 
and stored at -20 degrees Celsius until analysed. Samples were thawed when required for 
analysis in the Department of Human Nutrition Laboratory. Glucose was analysed on the 
Roche Hitachi Cobas c311 (Roche, Indianapolis, IN, USA) using enzymatic and 
enzymatic colorimetric methods (Appendix E). Insulin was analysed using an 
electrochemiluminescence immunoassay on the Roche Hitachi Cobas e411 (Appendix 
F).  
The glucose and insulin measurement procedures were standardized, with the same 
laboratory technician measuring blood glucose and insulin concentrations using the same 
methodology. Samples from both blood taking occasions were analysed together to 
eliminate intra run variability. Quality control was ensured by analyzing lyophilized 
standard control serums based on human serum for glucose (PreciControl ClinChem 
Multi 1 and 2, Roche, Indianapolis) and insulin (PreciControl Universal Level 1 and 1, 






The laboratories measuring satiety and cognition took place on the second and fourth 
Friday of March at the University of Otago Mellor Laboratories. Participants were asked 
to fast for two-hours before the laboratory and arrive to the laboratory at 12:00pm for 
lunch. The lunch protocol for the full 77 participants was identical to the	glycaemic	
response	laboratories (see glycaemic response laboratories section above).  
 
The first VAS questionnaire was filled in at 2:00pm (baseline), after which participants 
were asked to consume their beverage within ten minutes. After consumption of the 
beverage the VAS questionnaire was undertaken at: 30, 60, 90, 120, 150 and 180-
minutes. Films relevant to the cognitive testing were playing between these 30-minute 
intervals. The laboratory finished at 5:00pm.  
 
Questionnaires were pre-printed with student ID’s and placed at allocated seats in stapled 
order to ensure correct documentation.  
5.7.1 Measuring	satiety		
 
The VAS was composed of four 100mm lines with words anchored at each end, 
describing the extreme feelings of hunger, satisfaction, fullness and prospective food 
intake (29). The questions were: Question one (hunger): “how hungry do you feel?” 
(Not at all/ never been more hungry); Question two (satisfaction) “how satisfied do 
you feel?” (Completely empty/ cannot eat another bite); Question three (fullness) 
“How full do you feel?” (Not at all/ totally full); Question four (prospective food 
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intake) “how much do you think you can eat?” (Nothing at all/ a lot). These questions 
were asked in the same order at each time point.  
 
The participants were asked to make a mark on the line corresponding to their feelings 
of hunger seven times over a period of 180-minutes. The satiety was quantified by 
measuring the distance in mm from the start of the line to the mark made, providing a 
value between 0 and 100.  
 
At the first laboratory each participant attended they received electronic kitchen scales 
(Salter, model 3010, England), a diet record sheet (Appendix I) and asked to measure 
and record all food and drink they consumed after the laboratory until 12:00am.  Detailed 
instructions on how to complete a weighed diet record were verbally explained to the 
participants. The weighed diet record was then used to examine whether energy intakes 
on the day of the satiety test was different between test beverages.  
5.7.2 Dietary	analysis		
 
Participants were provided detailed instructions on how to enter their weighed diet record 
on the dietary assessment software Kaiculator (Appendix J). A programme developed by 
the Department of Human Nutrition at the University of Otago that uses the New Zealand 
food composition database “NZ FOODfiles” for dietary analyses (54). The entries were 
analysed to compare the subsequent energy intakes after the two test beverages.  
5.8 Demographic	and	anthropometric	questionnaire		
 
On arrival to one of the laboratories attended, before consumption of the sushi, all 
participants were weighed and measured in a standardized procedure using calibrated 
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electronic scales (Seca Alpha, model 770, Germany) and a freestanding calibrated 
stadiometer (Holtain Limited, Britain.). Participants were asked to remove their shoes and 
jackets. The measurements were used to calculate body mass index (BMI) by dividing 
weight in kilograms by height in metres squared (kg/m2). By the end of the study all 
participants had completed a single demographic questionnaire with information on sex, 
date of birth, ethnicity and their recorded weight and height (Appendix K).  
Ethnographic data was prioritized according to the Ministry of Health protocol and 
participants identifying as multiple ethnicities were only represented once (Table 6.1), 
with Maori taking priority over New Zealand European (55).   
5.9 Exercise	and	intake	questionnaires	
 
To check compliance and standardize procedures, glycaemic response participants were 
asked questions about alcohol consumption on the previous night, food and beverage 
intake between 10:00am and 12:00pm, food and beverage intake between 12:00pm and 
2:00pm and any exercise apart from walking undertaken between 12:00pm and 2:00pm 
(Appendix L). When measuring satiety and cognition all 77 participants were asked the 
above questions and additionally, if they had previously seen the documentary being 
shown that day for cognitive testing purposes. They were also asked if they knew which 




A sample of 60 was sufficient to detect a clinically relevant 400kJ change in subsequent 





The statistical analysis was completed by Dr Jill Haszard, a biostatistician within the 
Human Nutrition Department at the University of Otago. Statistical analyses of the data 
were completed using STATA/1C version 13.1 (StataCorp. 2013. Stata Statistical 
Software: Release 13. College Station, TX: StataCorp LP).  
 
Blood glucose and insulin concentrations were measured as incremental area under the 
curve (iAUC) for the twelve participants who undertook this part of the study. VAS 
results were measured as area under the curve (AUC), as this is the recommended 
analysis for multiple time points (56). Mean and standard deviation (SD) for each 
condition were reported. Mean differences between treatments, 95% confidence intervals 
(CIs) and p-values were calculated using mixed effects regression analysis, with the 
participant’s ID as a random effect and adjusting for randomized order. Only participants 
with complete data were included in the analysis.  
 
Differences in mean energy, fat, protein and carbohydrate intake after the laboratories 
were also assessed using mixed effects regression analysis, further adjusted for sex and 









Data from 69 participants were included in the analysis. Figure 6.1 shows the flow of 
participants through the study. Participants who did not take part on both testing 
occasions and thus had not consumed one of each beverage, were excluded from the 
analysis (n= 8).  
* The same individual was missing from both laboratories (n=1), therefore missing data from eight not nine people.  





Participant demographics are presented in Table 6.1. The age range of participants was 
19 to 39 years old (as of 23rd March 2017), with 87.3% under the age of 24. Of the total 
number of participants 70.4% had a body mass index (BMI) within the healthy range 
(18.5-24.9kg/m2), with 2.8% being classified as underweight (<18.5kg/m2) and 26.8% 
being classified as overweight or obese (>25kg/m2). Participants were predominantly 
female (81%) and of New Zealand European descent. Glycaemic response study 
participant demographics are presented in Table 6.2.  
Table 6.1: Demographic characteristics of satiety study participants (n= 69) 
 
Characteristics  Participants (n=69)  
Age, years (SD)1  22.0 (0.7) 
Sex, n (%)2 Female / Male 56 (81) / 13 (19) 
BMI, kg/m2 (SD)1  23.3 (2.7) 
Ethnicity, n (%)2 NZ European  42 (61)  
Maori 4 (6) 
Chinese  12 (17) 
Other 11 (16) 
1Results presented as mean (SD). 
2Results presented as n (%). 




Table 6.2: Demographic characteristics of glycaemic response study participants (n= 12) 
Characteristics  Participants (n=12)  
Age, years (SD)1  21.2 (1.4) 
Sex, n (%)2 Female / Male 10 (83) / 2 (17) 
BMI, kg/m2 (SD)1  21.9 (3.7) 
Ethnicity, n (%)2 NZ European  7 (58.3)  
Chinese  5 (41.7) 
1Results presented as mean (SD). 
2Results presented as n (%). 




Blood glucose and insulin concentrations are presented as the mean incremental area 
under the curve (iAUC) and standard deviation (SD) in Table 6.3. There was a 
significant difference in iAUC between the test beverages for both blood glucose and 
insulin concentrations (P<0.05), with the sucrose beverage producing a higher glycaemic 
































2493 (11540) 609 (1115) -1883 (-2846, 
921) 
0.001 
1 P-value <0.05 considered statistically significant. 
Abbreviations: CI= confidence interval, mmol/Ll= milomol per litre, µIULl= micro internal units per litre.  
 
 
An illustrative comparison of the mean incremental blood glucose and insulin 
concentrations of the test beverages from baseline (prior to consumption of the beverage) 
to 180-minutes after consumption of the beverage is shown in Figures 6.2 and 6.3. By 
the end of the sampling period (180-minutes) glucose concentrations were lower after the 
sucrose beverage (-1.9mmol/L) and insulin concentrations were lower after the 




Figure 6.2: Comparison of mean incremental blood glucose concentration following 
consumption of the test beverages.  
 
Figure 6.3: Comparison of mean incremental insulin concentration following 
















































































Results from VAS questionnaires assessing hunger, satisfaction, fullness and prospective 
food intake are presented as mean AUC and SD in Table 6.4. The AUC covers baseline 
to 180-minutes after consumption of the beverage. There were no significant differences 
in mean AUC for any VAS question at baseline or following consumption of the test 
beverages.  
 
For every hour the VAS score decreased on average by 18mm for the satisfaction and 
fullness questions, and increased on average by 18mm and 16mm for the hunger and 
prospective food intake questions, respectively.  
 
A sensitivity analysis that included the amount of energy participants consumed before or 












Table 6.4: Mean AUC and SD of VAS questions between the sucrose and isomaltulose 
sweetened beverages (n= 69) 
A visual illustration of the difference in appetite measured by the VAS’s is displayed in 
Figures 6.4, 6.5, 6.6 and 6.7. The higher the AUC for the VASs expressing hunger and 
prospective food intake (Figures 6.4 and 6.7) and the lower the AUC for the VASs 


































7143 (3569) 7197 (3745) 300 (-318, 919) 0.341 
1how hungry do you feel? 
2how satisfied do you feel? 
3how full do you feel? 
4how much do you think you can eat? 
*P –value <0.05 considered statistically significant.  













































































































































































The mean energy and macronutrient intake taken from participants’ weighed diet records 
are presented in Table 6.5. There were no significant differences in energy, fat, protein or 
carbohydrate intake following ingestion of the two test beverages.  
 
A sensitivity analysis that included the amount of energy participants consumed before or 
during the test had no appreciable impact on the effect sizes and significance of these 
results.  
 
Table 6.5: Mean (SD) energy and macronutrient intake from weighed diet records  
(n= 61)1 
 
















Protein (g) 41 (26) 39 (24) -2.3 (-8.8, 4.3) 0.498 
 




1Adjusted for BMI and sex.  
2 P-value <0.05 considered statistically significant.  











The aim of the study was to determine the effect of postprandial glycaemia (PPG) on 
satiety using an isomaltulose sweetened beverage compared to a sucrose sweetened 
beverage within a healthy New Zealand population. By design it was confirmed that 
participants’ glycaemic and insulinaemic responses were lower following ingestion of the 
isomaltulose compared with the sucrose beverage. The crossover design allowed an 
individual comparison of glycaemic response, important for eliminating inter-individual 
variation (13). Despite the differences in postprandial glycaemic and insulinaemic 
responses, there were no significant differences in either subjective satiety assessed using 
visual analogue scales (VASs) or by an objective measure of subsequent food intake.  
 When comparing the current study to similar designed studies results are 
consistent. This is likely attributed to the double-blinding that eliminates participant and 
researcher bias and the crossover design which allows for participants to be their own 
control. Two comparable studies measured subjective appetite and energy intake for three 
and four-hours after consumption of low, intermediate and high-glycaemic index (GI) 
beverages (57, 58). Test beverages included a glucose, full milk, and half glucose, half 
milk beverage and a fructose, glucose, and whey protein beverage, all of which were 
1100kJ (57, 58). Despite significant changes in glycaemic response to the beverages in 
these double-blind, randomised crossover trials, no differences in subjective appetite via 
VASs or ad libitum energy intake was observed (57, 58).  
Generalisability of finding no difference in satiety despite changes in PPG within young 
healthy adult participants is broadened because Brindal and colleagues used children 
participants and Bowen and colleagues used overweight participants (57, 58). 
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 Our study’s lack of effect on satiety despite differences in PPG is not in accord 
with the glucostatic mechanism of food intake proposed by Mayer (6). The glucostatic 
theory states that temporary increases in blood glucose concentrations correspond to a 
decrease in food intake and vice versa (6). A study comparing short-term (one-hour) 
satiety after consumption of high and low-GI isoenergetic beverages, found that the high-
GI beverage kept participants fuller at 60-minutes, in accordance with the glucostatic 
theory (59). It was thus hypothesised that high-GI keeps you fuller short-term and low-GI 
may sustain satiety long-term (59). However, our findings did not support this hypothesis 
or show any relationship between blood glucose concentrations and satiety.  
 In contrast, differences in satiety have been found in other studies that also 
compared low and high glycaemic treatments. One such study conducted in obese 
adolescent males comparing ad libitum food intake after low, intermediate or high-GI 
meals, reported voluntary energy intake after the high-GI meal was 81% greater than 
after the low-GI meal (60).  However, the low-GI meal contained more protein, more fat 
and less carbohydrate than the high-GI meal (60). Furthermore, the high-GI meal was 
mainly liquid, compared with the predominantly solid low-GI meal that required chewing 
(60). Evidence suggests that solid food is more satiating than liquids (57, 61, 62), and that 
chewing elicits a higher degree of satiety due to alterations in gut hormone responses 
(63). A randomised crossover study fed participants a breakfast meal with 50g of 
available carbohydrate with various GI values and energy and macronutrient contents, 
and found no relationship between glycaemic response and short-term appetite (64). The 
low-GI breakfast meal was associated with reduced energy intake at lunch, but 
subsequent energy intake may have been influenced by the fact the low-GI meal 
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contained a higher energy content (64).  A randomised controlled trial that measured 
glycaemic response and satiety after consumption of a low-GI carob or high-GI chocolate 
cookie, reported increased satiety after the low-GI cookie (65). However, the low-GI 
carob cookie contained 9.60 more grams of dietary fibre and 9.15 more grams of 
monounsaturated fats, due to the carob cookie containing 23g of ground hazelnuts, which 
the chocolate cookie did not (65). These studies indicate that low opposed to high-GI 
foods and beverages result in greater satiety (60, 64, 65). However, it is likely that factors 
other than glycaemic response such as fibre, macronutrient and energy content, 
contributed to, or were the cause of, the differences in satiety found. 
 Confounding factors are particularly prominent in long-term studies, thus how 
PPG effects health over an extended period of time is not well understood. There appears 
to be little relationship between the GI of foods and weight gain over periods of months 
and years (27, 32, 66). This is likely attributable to the GI of foods being unrelated to the 
energy density of foods, for example cake and apples have comparable GI’s but very 
different energy densities (30). However, some studies have reported a reduction in heart 
disease and improvement in glycaemic control through following a low glycaemic diet 
long-term in overweight and insulin resistant individuals (1, 22, 67, 68). Furthermore, it 
is not clear whether these benefits are independent of the effects of the dietary fibre 
present in the low glycaemic foods consumed (68). 
 An acute feeding study that fed participants isoenergetic portions of food with 
differing GI’s suggests that food volume or the energy density, is the strongest predictor 
of satiety (30). Our findings support this hypothesis as both beverages were isovolumetric 
and isoenergetic, however despite a difference in glycaemic response no difference in 
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VAS scores or ad libitum intake was observed. By using a beverage, we were able to 
keep energy density the same whilst controlling macronutrient and energy content. 
However, the liquid form of our treatments may have reduced overall feelings of satiety 
compared with solid foods (57, 61, 62). This could be attributable to fluids being ingested 
more quickly, an increased rate of gastric emptying, lack of gastric distention, the act of 
swallowing without chewing, and potential cognitive bias of solid foods having a 
perceived higher energy intake (62, 69). Nevertheless, the finding of a lack of difference 
in feelings of satiety following treatments having differing glycaemic potential is 
important, especially as consumption of energy-dense sweetened beverages is a major 
public health concern (70).  
 Glucose and fructose have been found to influence satiety and metabolic markers 
differently, despite having the same caloric value and displaying a similar pattern of 
weight gain over a period of 10-weeks in overweight and obese subjects (71). When 
assessing the metabolic effects of fructose or glucose sweetened beverages, glucose 
consumption reduced cerebral blood flow in regions of the brain responsible for appetite 
and reward processing, when compared to fructose (71-73). Thus, the greater activation 
of brain regions following fructose consumption has been thought to promote feeding 
behaviour (73). It can therefore be hypothesised that there are additional mechanisms of 
satiety after sweetened beverage consumption independent of the glycaemic response. A 
benefit of using isomaltulose and sucrose as comparison treatments is that identical 
monosaccharides were involved. 
 The present study is the first to assess the satiating properties of isomaltulose 
compared to sucrose in humans. A Japanese study comparing the satiation of sucrose to 
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isomaltulose in rats found that isomaltulose was significantly more satiating when the 
sugars were consumed in liquid form (47). These results were not in agreement with the 
present study, indicating that studies where isomaltulose has been tested in animals may 
not be correlated well to humans.   
7.1 Clinical	implications	
 
The results from the current study suggest that despite differences in PPG there is no 
difference in satiety following the ingestion of sucrose and isomaltulose sweetened 
beverages. Those with diabetes mellitus may benefit from consumption of the 
isomaltulose beverage, in comparison to the sucrose beverage, due to its low and 
sustained effect on blood glucose concentrations, thus minimizing hyperglycaemia which 
is independently associated with cardiovascular disease (CVD), retinopathy, certain 
cancers and other serious complications in those with diabetes (12). However, 
isomaltulose has the same caloric value as sucrose (9) and consumption should be limited 
in those who are obese or overweight.  
 Sugary beverages are a significant source of energy in the Western diet and 
possess no beneficial nutritional properties (61). High intakes are associated with obesity, 
type 2 diabetes, gout, coronary heart disease (CHD), and CVD, and thus should be 
limited (70).  Most studies that have demonstrated the health benefits of low glycaemic 
foods involved natural and minimally processed carbohydrate containing cereals, 
vegetables and fruit (18). These naturally occurring low-GI foods have qualities 
independent of their GI that are beneficial for our health, such as fibre. Thus, the claim 
that low-GI keeps you fuller for longer (2), could be attributed to the varying properties 
of these low-GI foods and not the GI itself. Food choices should not be made solely on 
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the GI of a food, as processed foods can possess a low-GI whilst also having a substantial 
amount of sugar and undesirable fat (18).  
7.2 Strengths	and	limitations	
 
The study used a sample of healthy, young nutrition students, limiting the applicability of 
the findings to the wider population. However, the use of a crossover study design 
strengthened this study as participants acted as their own control, and double-blinding 
eliminated bias with preconceived ideas of low-GI keeping you fuller for longer. The use 
of a beverage made double-blinding easy whilst allowing for control of volume, 
monosaccharide composition and macronutrient and energy content.  
 An important aspect of this study was using both VASs and weighed diet records 
to measure satiety, as although VASs are a validated tool, they only measure subjective 
feelings of hunger (29). Furthermore, VASs have been found to be less accurate for 
finding significant differences when compared to weighed diet records (8). The use of a 
500mL beverage with 50g of sugar was used as it is relative to commonly consumed 
sugar sweetened beverages (50), making this study relevant to the real world. A novel 
aspect of this study was that it was conducted in the afternoon, as studies measuring 
satiety are commonly conducted in the morning (57, 59, 60, 64, 73, 74), when the impact 
of satiety is just as important in the afternoon for reducing daily energy intake and 
preventing weight gain. However, we may have been able to generate a larger difference 
in glycaemic response if the study had been conducted in the morning after an overnight 
fast, which may have had a more pronounced effect on satiety. Nonetheless, the use of a 
beverage without fat or protein, both known to dampen glycaemic response (75), allowed 
us to maximize glycaemic response with our afternoon study design.  
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 An unavoidable limitation of this study is the use of self-reported data. 
Participants may not have read the VASs correctly, in turn not accurately marking their 
feelings of appetite. Additionally, participants could have fabricated their weighed diet 
records or not entered their data correctly onto the dietary analysis software. To 
strengthen the study, a placebo could have been used to compare the satiation of the two 
test beverages too. The energy dense test beverages, may have not affected satiety 
compared to a non-caloric sweetened beverage, adding empty calories and promoting 
weight gain. Thus, a study comparing sucrose and isomaltulose to a placebo may be an 
area for further research.  
7.3 Conclusion	and	recommendations	
 
In a healthy, young cohort of participants, glycaemic response varied significantly after 
consumption of a sucrose and isomaltulose beverage. However, no significant differences 
were found when measuring satiety using VASs and weighed diet records to analyse 
subsequent energy intake. From these results, we can infer that there was no relationship 
between glycaemic response and satiety in this study. For those with or at risk of diabetes 
or overweight or obese, it would be sensible to recommend limiting all sugar sweetened 
beverage consumption, regardless of the GI, and choose wholesome foods that induce a 








Part A: the applicability and relevance of the research to dietetic practice  
 
Despite the differences in postprandial glycaemia (PPG) after consumption of the sucrose 
and isomaltulose beverages, there were no significant differences in either subjective 
satiety assessed using visual analogue scales (VASs) or subsequent food intake. A 
possible reason for this finding could be the liquid form of our treatments, as liquids are 
less satiating than solids (57, 61, 62), and that the beverages contained no additional 
nutritional properties that would promote satiety.  
 This research has challenged the common misconception about low-glycaemic 
index (GI) keeping you fuller for longer and has confirmed that this does not apply to 
beverages made with isomaltulose. When advising future clients, I will be cognisant of 
this fact and take extra care when advising on the suitability of low-GI meals, by 
suggesting low-GI foods rather than beverages, whilst ensuring those low-GI foods are 
nutrient dense and known to be associated with increased satiation.  
 As a dietitian, I would be careful in my advice to patients who have diabetes or 
are on weight loss diets, regarding isomaltulose use. Due to the low glycaemic response 
of isomaltulose, it may be considered as a sugar alternative to those with diabetes. 
However, it contains the same energy content as sucrose (9) and thus should be limited in 
those who are either obese or overweight.  
 Undertaking this research has also given me the opportunity to learn other 
beneficial skills such as how to critically review and evaluate the literature. This will be 
invaluable when working as a dietitian in using evidence based literature to keep me up 
to date with the latest research. 
	 	 	
49	
Part B: Reflective Practice: What this research experience has meant to me 
An aspect of my research journey that stands out as being particularly important for my 
growth and development as a dietitian, was working alongside my Master of Dietetics 
(MDiet) research partner (CK). I was initially hesitant to be undertaking a research 
project with a partner as I have always been an independent worker. However, working 
with CK proved to be incredibly beneficial and actually far more enjoyable than I initially 
anticipated. I quickly adapted and learned how to work as an efficient team member, 
contributing ideas and discussing solutions to problems openly. This was particularly 
evident in designing and implementing the experimental phase of the study, as there were 
some methodological issues that occurred that CK and I had to be quick to resolve.  
 Firstly, we ran out of specific ingredients needed for making the beverages, 
requiring us to get in touch with multiple members of staff who were responsible for 
ordering and finances. However, it also required us to implement a back up plan in case 
the supplies did not arrive in time. Secondly, due to participant error we had to alter the 
protocol for the second laboratory testing session to keep methodological procedures the 
same, thus ensuring the tests were comparable. When faced with these problems we 
worked together to resolve them, teaching us how to be adaptable under pressure and 
improving our problem solving skills immensely.  
 This positive experience working alongside CK prompted me to become a 
member of the MDiet thesis writing group. This group met weekly and implemented a 
feedback system where we would read sections of each other’s thesis chapters and 
provide feedback. It was advantageous to not only read colleagues’ work but also to get 
feedback to help improve the clarity in my writing of this thesis.  
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 By working so closely with CK and other MDiet colleagues, I believe I have 
gained outstanding teamwork, communication, problem solving and organizational skills. 
Although I had to regularly communicate with lots of different people (supervisors, 
laboratory technicians, biostatistician) throughout this process, I continued to work 
alongside CK for the duration of the research and write up. By working in partnership 
with CK, we continued to communicate our ideas, and resolve problems whilst still 
remaining highly organized during this stressful time. These skills will have a lifelong 
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Manager, Academic Committees, Mr Gary Witte
H17/011
Dr B Venn
Department of Human Nutrition
Division of Sciences
Dear Dr Venn,
I am again writing to you concerning your proposal entitled “HUNT311 clinical nutritional
laboratory; a repeated teaching activity”, Ethics Committee reference number H17/011.
Thank you for your request for the amendment to give students a sweet beverage containing
50mg of sucralose instead of a “trifle”. Thank you for keeping the Committee informed.
Your proposal continues to be fully approved by the Human Ethics Committee. If the nature,
consent, location, procedures or personnel of your approved application change, please






 c.c. Professor S Samman    Department of Human Nutrition
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Trial ID  
ACTRN12618000901202  
Ethics application status  
Approved  
Date submitted  
25/05/2018  
Date registered  
29/05/2018  
Date last updated  
Type of registration  
Retrospectively registered  
 
Public title  
Effect on satiety and cognitive function following the ingestion of beverages containing 
sucrose or isomaltulose by healthy adults  
 
Scientific title  
The effect in healthy adults of consuming sucrose or isomaltulose sweetened beverages 
on measures of satiety and cognitive function  
 
Universal Trial Number (UTN)  
U1111-1214-7109  
 




Condition category  
Condition code  
Diet and Nutrition  
 
Other diet and nutrition disorders  
Metabolic and Endocrine  





Study type  
Interventional  
 
Description of intervention(s) / exposure  
This will be a double-blind crossover trial in which 75 healthy adults will ingest a 500ml 
sparkling water beverage containing either 50g of sucrose or a beverage containing a mix 
of 50g isomaltulose with 45mg sucralose. The order in which participants receive the 
beverages will be randomised to each person. There will be a minimum 2 day washout 
between beverages. Prior to the intervention, participants will be given a standard lunch 
of sushi and water. Participants will ingest the intervention beverages within 15 minutes 
1.5hr following lunch. Eating lunch and subsequent assessment of satiety and tests of 
cognition will be under the supervision of the study investigators.  
 
Intervention code [1]  
Treatment: Other  
Comparator / control treatment  
This is a crossover trial with the sucrose beverage used as the comparator  




Primary outcome [1]  
Satiety assessed via the use of visual analogue scales (Likert) in response to four appetite 
questions (subjective).  
Timepoint [1]  
Subjective satiety will be quantified at baseline and at 30, 60, 90, 120 and 150 minutes 
following beverage ingestion.  
 
Primary outcome [2]  
A composite outcome comprising a battery of tests of cognitive function (word recall; 
audio-visual memory; trailmaking)  
Timepoint [2]  
Tests of cognition will be quantified at 45, 90 and 135 minutes following beverage 
ingestion.  
 
Primary outcome [3]  
Satiety assessed as subsequent energy intake  
Timepoint [3]  
Food and beverages ingested from 12pm to 12am of each test day  
 
Secondary outcome [1]  
Postprandial monitoring of blood glucose concentrations over a period of 3h following 
beverage ingestion.  
Timepoint [1]  
Capillary blood will be sampled via fingerprick at baseline at 30, 60, 90, 120 and 150 





Key inclusion criteria  
Healthy adults  
Minimum age  
18 Years  
Maximum age  
75 Years  
Gender  
Both males and females  
Can healthy volunteers participate?  
Yes  
Key exclusion criteria  
Intolerance to isomaltulose or sucralose  
 
Study design  
Purpose of the study  
Treatment  
Allocation to intervention  
Randomised controlled trial  
Procedure for enrolling a subject and allocating the treatment (allocation concealment 
procedures)  
All participant names will be entered into a dataset. A random number generator will be 
used to generate a random number next to each participant. The dataset will be sorted in 
ascending random number order. On the first test day, the first 37 participants in the 
sorted dataset will be allocated one treatment and the last 38 participants the alternative 
treatment; on the second test day, the treatments will be reversed (crossover). 
Randomisation and the supply of beverages to participants will be undertaken by a 
University staff member otherwise uninvolved in the study. Allocation concealment was 
achieved by central randomisation by computer.  
Methods used to generate the sequence in which subjects will be randomised (sequence 
generation)  
Simple randomisation using a randomisation table created by computer software  
Masking / blinding  
Blinded (masking used)  
Who is / are masked / blinded?  
The people receiving the treatment/s  
The people administering the treatment/s  
The people assessing the outcomes  
The people analysing the results/data  
Intervention assignment  
Crossover  
Other design features  
Phase  
Not Applicable  




Statistical methods / analysis  
Using published data and assuming a within-person correlation of 0.5, a sample size of 70 
is sufficient to detect a difference of 0.5 SD for the quality of memory, trailmaking and 
speed of attention tests using ANCOVA (Scholey et al., 2004). For satiety, 70 
participants will have 80% power to detect a 5mm difference in VAS scores between 
trifles (Flint et al., 2000). To allow for dropout, 75 people will be recruited. 
 
Scholey, AB and Kennedy, DO, Cognitive and physiological effects of an "energy 
drink": an evaluation of the whole drink and of glucose, caffeine and herbal flavouring 
fractions, Psychopharmacology (Berl), 2004; 176: 320-30. 
 
Flint, A, Raben, A, Blundell, JE and Astrup, A, Reproducibility, power and validity of 
visual analogue scales in assessment of appetite sensations in single test meal studies, Int 
J Obes Relat Metab Disord, 2000; 24: 38-48. 
 
Recruitment  
Recruitment status  
Completed  












Sample size  
Target  
75  
Accrual to date  
Final  
75  




Brief summary  
It has been postulated that satiety and cognitive function are dependent upon the 
concentration of circulating blood glucose. The primary purpose of the study therefore, is 
to test whether measures of satiety and cognition are effected by differing concentrations 
of circulating blood glucose concentrations. To generate differences in blood glucose 
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concentration, beverages sweetened with 50g of either sucrose or isomaltulose were 
developed. In order to match the beverages for sweetness, a small amount of sucralose 
was added to the isomaltulose beverage. A triangle taste test was undertaken in six people 
with the result that the two beverages were indistinguishable from one another. The blood 
glucose response to the test beverages was undertaken in a subset of 12 of the 75 
participants. The tests of satiety and cognition were conducted in the afternoon. The order 
in which participants received the test beverages was randomised to each person. Each 
participant consumed both of the test drinks in a crossover design with a washout of at 
least two days. Standard test methodology was used to test for subjective and objective 
satiety. During the test period of three hours, a film was shown in three half hour time-
slots with a 20 minute interval between each showing. During the three intervals, a 
standard word recall test was administered and participants answered questions relating 
to the section of film that had just been screened. One trailmaking test was administered 
at the end of each session. The people administering the tests and the participants were 
unaware of which beverage had just been consumed (double-blinding). Data analysis was 
undertaken by a biostatistician blinded to order of treatment. The study hypothesis was 
that a more stable blood glucose concentration over time, represented by the isomaltulose 








Bernard Venn  
Address  
Department of Human Nutrition 
University of Otago 
PO Box 56 
Dunedin 9054  
Country  













Appendix C: Consent form  
 
HUNT311 clinical nutritional laboratory; a repeated teaching activity  
Principal Investigator: Dr Bernard Venn (bernard.venn@otago.ac.nz tel 034795068) 
CONSENT FORM FOR PARTICIPANTS 









































Signature of participant:  Date: 
   
   
 
Name of person taking consent  Date: 














                How hungry do you feel? 
 
       





              How satisfied do you feel? 
 
 




                  
                     How full do you feel? 
 
 




       
                  How much do you think you can eat? 
 
 
_______________________________________________   
 
       
   
I have never 
been more 
hungry 
I am not 
hungry at 
all 
I cannot eat 
another bite 




















• Indicates cobas c systems on which reagents can be used
Order information Roche/Hitachi cobas c systems
Glucose HK cobas c 311 cobas c 501/502
800 tests Cat. No. 04404483 190 System-ID 07 6831 6 • •
Calibrator f.a.s. (12 x 3 mL) Cat. No. 10759350 190 Code 401
Calibrator f.a.s. (12 x 3 mL, for USA) Cat. No. 10759350 360 Code 401
Precinorm U plus (10 x 3 mL) Cat. No. 12149435 122 Code 300
Precinorm U plus (10 x 3 mL, for USA) Cat. No. 12149435 160 Code 300
Precipath U plus (10 x 3 mL) Cat. No. 12149443 122 Code 301
Precipath U plus (10 x 3 mL, for USA) Cat. No. 12149443 160 Code 301
Precinorm U (20 x 5 mL) Cat. No. 10171743 122 Code 300
Precipath U (20 x 5 mL) Cat. No. 10171778 122 Code 301
PreciControl ClinChem Multi 1 (20 x 5 mL) Cat. No. 05117003 190 Code 391
PreciControl ClinChem Multi 1 (4 x 5 mL, for USA) Cat. No. 05947626 160 Code 391
PreciControl ClinChem Multi 2 (20 x 5 mL) Cat. No. 05117216 190 Code 392
PreciControl ClinChem Multi 2 (4 x 5 mL, for USA) Cat. No. 05947774 160 Code 392
Diluent NaCl 9 % (50 mL) Cat. No. 04489357 190 System-ID 07 6869 3
English
System information
For cobas c 311/501 analyzers:
GLUC3: ACN 717
SGLU3: ACN 668 (STAT, reaction time: 7)
For cobas c 502 analyzer:
GLUC3: ACN 8717
SGLU3: ACN 8668 (STAT, reaction time: 7)
Intended use
In vitro test for the quantitative determination of glucose in human serum,
plasma, urine and CSF on Roche/Hitachi cobas c systems.
Summary1,2,3
Glucose is the major carbohydrate present in the peripheral blood. Oxidation
of glucose is the major source of cellular energy in the body. Glucose
derived from dietary sources is converted to glycogen for storage in the
liver or to fatty acids for storage in adipose tissue. The concentration of
glucose in blood is controlled within narrow limits by many hormones, the
most important of which are produced by the pancreas.
The most frequent cause of hyperglycemia is diabetes mellitus resulting
from a deficiency in insulin secretion or action. A number of secondary
factors also contribute to elevated blood glucose levels. These include
pancreatitis, thyroid dysfunction, renal failure and liver disease.
Hypoglycemia is less frequently observed. A variety of conditions may cause
low blood glucose levels such as insulinoma, hypopituitarism or insulin
induced hypoglycemia. Glucose measurement in urine is used as a diabetes
screening procedure and to aid in the evaluation of glycosuria, to detect
renal tubular defects, and in the management of diabetes mellitus. Glucose
measurement in cerebrospinal fluid is used for evaluation of meningitis,
neoplastic involvement of meninges and other neurological disorders.
Test principle
UV test
Enzymatic reference method with hexokinase4,5





Glucose-6-phosphate dehydrogenase oxidizes glucose-6-phosphate in
the presence of NADP to gluconate-6-phosphate. No other carbohydrate
is oxidized. The rate of NADPH formation during the reaction is directly
proportional to the glucose concentration and is measured photometrically.
G-6-P + NADP+
G-6-PDH
gluconate-6-P + NADPH + H+
Reagents - working solutions
R1 MES buffer: 5.0 mmol/L, pH 6.0; Mg2+: 24 mmol/L; ATP: ≥ 4.5 mmol/L;
NADP: ≥ 7.0 mmol/L; preservative
R2 HEPES buffer: 200 mmol/L, pH 8.0; Mg2+: 4 mmol/L; HK (yeast):
≥ 300 µkat/L; G-6-PDH (E. coli): ≥ 300 µkat/L; preservative
R1 is in position B and R2 is in position C.
Precautions and warnings
For in vitro diagnostic use.
Exercise the normal precautions required for handling all laboratory reagents.
Safety data sheet available for professional user on request.





Shelf life at 2-8 °C: See expiration date on
cobas c pack label.
On-board in use and refrigerated on the analyzer: 8 weeks
Diluent NaCl 9 %
Shelf life at 2-8 °C: See expiration date on
cobas c pack label.
On-board in use and refrigerated on the analyzer: 12 weeks
Specimen collection and preparation
For specimen collection and preparation, only use suitable
tubes or collection containers.
Only the specimens listed below were tested and found acceptable.
Serum.
Plasma: Li-heparin, K2-EDTA, NaF/Na2EDTA, KF/Na2EDTA, NaF/K-Oxalate.
Collect blood by venipuncture from fasting individuals using an evacuated
tube system. The stability of glucose in specimens is affected by storage
temperature, bacterial contamination, and glycolysis. Plasma or serum
samples without preservative (NaF) should be separated from the cells or
clot within half an hour of being drawn. When blood is drawn and permitted
to clot and to stand uncentrifuged at room temperature, the average
decrease in serum glucose is ~ 7 % in 1 hour (0.28 to 0.56 mmol/L or
5 to 10 mg/dL). This decrease is the result of glycolysis. Glycolysis can
be inhibited by collecting the specimen in fluoride tubes.1
The sample types listed were tested with a selection of sample collection tubes
that were commercially available at the time of testing, i.e. not all available
tubes of all manufacturers were tested. Sample collection systems from
various manufacturers may contain differing materials which could affect
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cobas e 411 cobas e 601 cobas e 602
• • • • •
English
Intended use
Immunoassay for the in vitro quantitative determination of human insulin
in human serum and plasma. The determination of insulin is utilized in the
diagnosis and therapy of various disorders of carbohydrate metabolism,
including diabetes mellitus and hypoglycemia.
The electrochemiluminescence immunoassay “ECLIA” is intended for
use on Elecsys and cobas e immunoassay analyzers.
Summary1,2,3,4,5
Insulin is a peptide hormone with a molecular weight of approximately
6000 daltons. It is secreted by the B-cells of the pancreas and
passes into circulation via the portal vein and the liver. Insulin is
generally released in pulses, with the parallel glucose cycle normally
about 2 minutes ahead of the insulin cycle.1
The insulin molecule consists of two polypeptide chains, the α-chain with
21 and the β-chain with 30 amino acids. Biosynthesis of the hormone takes
place in the β-cells of the islets of Langerhans in the form of single-chain
preproinsulin, which is immediately cleaved to give proinsulin. Specific
proteases cleave proinsulin to insulin and C-peptide which pass into the
bloodstream simultaneously. About half of the insulin, but virtually none of
the C-peptide, is retained in the liver. Circulating insulin has a half-life of
3-5 minutes and is preferentially degraded in the liver, whereas inactivation or
excretion of proinsulin and C-peptide mainly takes place in the kidneys.
The amino acid sequence of insulin has remained surprisingly constant
during evolution, with the result that prior to the development of genetically
engineered human insulin it was possible to successfully use porcine
or bovine insulin in the therapy of diabetes mellitus.2
The action of insulin is mediated by specific receptors and primarily consists
of facilitation of the uptake of sugar by the cells of the liver, fatty tissue
and musculature; this is the basis of its hypoglycemic action.
Serum insulin determinations are mainly performed on patients with
symptoms of hypoglycemia. They are used to ascertain the glucose/insulin
quotients and for clarification of questions concerning insulin secretion,
e.g. in the tolbutamide test and glucagon test or in the evaluation of oral
glucose tolerance tests or hunger provocation tests.
Although the adequacy of pancreatic insulin synthesis is frequently assessed
via the determination of C-peptide, it is still generally necessary to determine
insulin. For example, therapeutic administration of insulins of non-human origin
can lead to the formation of anti-insulin antibodies. In this case, measurement
of the concentration of serum insulin shows the quantity of free - and hence
biologically active - hormone, whereas the determination of C-peptide provides
a measure of the patient’s total endogenous insulin secretion.3,4
A disorder in insulin metabolism leads to massive influencing of a number of
metabolic processes. A too low concentration of free, biologically active insulin
can lead to the development of diabetes mellitus. Possible causes of this
include destruction of the β-cells (type I diabetes), reduced activity of the insulin
or reduced pancreatic synthesis (type II), circulating antibodies to insulin,
delayed release of insulin or the absence (or inadequacy) of insulin receptors.
On the other hand, autonomous, non-regulated insulin secretion is generally
the cause of hypoglycemia. This condition is brought about by inhibition of
gluconeogenesis, e.g. as a result of severe hepatic or renal failure, islet cell
adenoma, or carcinoma. Hypoglycemia can, however, also be facilitated
intentionally or unintentionally (factitious hypoglycemia).
In 3 % of persons with reduced glucose tolerance, the metabolic state
deteriorates towards diabetes mellitus over a period of time. Reduced glucose
tolerance during pregnancy always requires treatment. The clearly elevated
risk of mortality for the fetus necessitates intensive monitoring.
The Elecsys Insulin assay employs two monoclonal antibodies which
together are specific for human insulin.
Test principle
Sandwich principle. Total duration of assay: 18 minutes.
• 1st incubation: Insulin from 20 µL sample, a biotinylated monoclonal
insulin-specific antibody, and a monoclonal insulin-specific antibody
labeled with a ruthenium complexa form a sandwich complex.
• 2nd incubation: After addition of streptavidin-coated microparticles,
the complex becomes bound to the solid phase via interaction
of biotin and streptavidin.
• The reaction mixture is aspirated into the measuring cell where the
microparticles are magnetically captured onto the surface of the
electrode. Unbound substances are then removed with ProCell/ProCell M.
Application of a voltage to the electrode then induces chemiluminescent
emission which is measured by a photomultiplier.
• Results are determined via a calibration curve which is
instrument-specifically generated by 2-point calibration and a
master curve provided via the reagent barcode.
a) Tris(2,2’-bipyridyl)ruthenium(II)-complex (Ru(bpy)2+3 )
Reagents - working solutions
M Streptavidin-coated microparticles (transparent cap), 1 bottle, 6.5 mL:
Streptavidin-coated microparticles 0.72 mg/mL; preservative.
R1 Anti-insulin-Ab~biotin (gray cap), 1 bottle, 10 mL:
Biotinylated monoclonal anti-insulin antibody (mouse) 1 mg/L;
MES buffer 50 mmol/L, pH 6.0; preservative.
R2 Anti-insulin-Ab~Ru(bpy)2+3 (black cap), 1 bottle, 10 mL:
Monoclonal anti-insulin antibody (mouse) labeled with ruthenium
complex 1.75 mg/L; MES buffer 50 mmol/L, pH 6.0; preservative.
Precautions and warnings
For in vitro diagnostic use.
Exercise the normal precautions required for handling all laboratory reagents.
Disposal of all waste material should be in accordance with local guidelines.
Safety data sheet available for professional user on request.
Avoid foam formation in all reagents and sample types (specimens,
calibrators, and controls).
Reagent handling
The reagents in the kit have been assembled into a ready-for-use
unit that cannot be separated.
All information required for correct operation is read in from
the respective reagent barcodes.
Storage and stability
Store at 2-8 °C.
Store the Elecsys Insulin reagent kit upright in order to ensure complete
availability of the microparticles during automatic mixing prior to use.
Stability:
unopened at 2-8 °C up to the stated expiration date
after opening at 2-8 °C 12 weeks
on the analyzers 4 weeks
Specimen collection and preparation
Only the specimens listed below were tested and found acceptable.
Serum collected using standard sampling tubes or tubes
containing separating gel.
Li-heparin, K3-EDTA, and sodium citrate plasma.
Hemolysis interferes, as insulin-degrading peptidases are
released from erythrocytes.6
Criterion: Recovery within 90-110 % of serum value or slope 0.9-1.1 + intercept
within < ± 2 x analytical sensitivity (LDL) + coefficient of correlation > 0.95.
Stable for 24 hours at 2-8 °C, 6 months at -20 °C. Freeze only once.7
The sample types listed were tested with a selection of sample collection tubes
that were commercially available at the time of testing, i.e. not all available
tubes of all manufacturers were tested. Sample collection systems from
various manufacturers may contain differing materials which could affect
the test results in some cases. When processing samples in primary tubes
(sample collection systems), follow the instructions of the tube manufacturer.
Centrifuge samples containing precipitates before performing the
assay. Do not use heat-inactivated samples. Do not use samples
and controls stabilized with azide.
2012-04, V 13 English 1 / 4 Elecsys and cobas e analyzers
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510(k) Summary - PreciControl ClinChem Multi I and 2
Introduction Roche Diagnostics Corporation hereby submits this 5 10(k) to provide
notification of our intent to market new controls named PreciControl
ClinChem Multi 1 and 2.
Submitter Roche Diagnostics
name, address,' 9115 Hague Rd.




Contact Person: Patrick Stimart
Date prepared: July 16, 2010
Device Name(s) Proprietary namne(s): 1. PreciControl ClinChem Multi 1 and 2
Common name(s): PCCC Multi 1 and 2
Classified under 21 CFR 862.1660
Classification name(s): Multi-analyte controls, all kinds (assayed and
unassayed)
Product Code: JJ`Y
Device The PreciControl ClinChem Multi 1 and 2 are quality control products
Description consisting of lyophilized human sera with constituents added as
required to obtain desired component levels. Concentrations of the
components in the controls have been adjusted to represent normal
and pathological levels. The concentrations of the components in the
controls are lot-specific and representative values are given in the
enclosed value sheets.
Continued on next page
Page 1 of 4
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510(k) Summary - PreciControl Universal
Introduction According to the requirements of 21 CFR 807.92, the following information
provides sufficient detail to understand the basis for a determination of
substantial equivalence.
Submitter Roche Diagnostics
name, address, 9115 Hague Road
contact Indianapolis, IN 46250
317-521-3723
Contact Person: Gail Sauers
Date Prepared: February 27, 2009
Submission Roche Diagnostics hereby submits this Traditional 5 10(k) device
purpose modification to provide notification of changes to our control material,
Elecsys PreciControl Universal (PCU).
PreciControl Universal is used for quality control of Elecsys immunoassays
on the Elecsys and cobas e immunoassay analyzers. This product contains
control material for numerous Elecsys assays in one convenient solution.
Changes to PCU consist of the addition of Carcinoembryonic antigen (CEA)
control and total (free + complexed) Prostate-Specific Antigen (PSA) to
extend the current functionality.
Device Name Proprietary name: Elecsys PreciControl Universal.
Common name: PreciControl Universal
Classification name: Multi-Analyte Controls, All Kinds (assayed and
Unassayed)
Device The Elecsys PreciControl Universal is a lyophilized product consisting of
Description added antigens in a human serum matrix. During manufacture, the analytes
are spiked into the matrix at the desired concentration levels.
Intended use Elecsys PreciControl Universal is used for quality control of Elecsys
immunoassays on the Elecsys and cobas e immunoassay analyzers.
Continued on next page
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Appendix I: Diet record sheet 
ID: 
HUNT311 Glycaemic Laboratory   
 









































* PTO – if you need more space to write your foods and drinks please tick at the 




Appendix J: Kaiculator instruction 
Logging on: 
Open the Firefox or Chrome web browser 
Type https://sybil.otago.ac.nz/dietary/opening.das? in the address line 
The ‘Username’ is your University user name and the ‘password’ is your student ID 
number 
There are clickable ‘Help ’  and ‘FAQ’  icons at the bottom right of most screens 
which give instructions for each screen. Below is a summary of what you need know. 
How to enter a diet within a project: 
Select the project e.g. HUNT311 > select Diets > select Records > select New 
Set up the record: 
Record the Record ID number, usually the study participant ID number. Kai-culator 
produces a default ID RRRXXX but overide this with your chosen unique ID e.g. your 
name or student ID to make up 6 letters with no spaces in between. If students share the 
same name, e.g., four students named ‘Alex’ ensure your Record IDs are all different.  
NB be careful when you record the ID. You cannot change it if you make a mistake. You 
can e-mail Liz to change an ID for you (liz.fleming@otago.ac.nz). Send her the incorrect 
ID and the new correct ID. Liz can not change the Record IDs if students use the same 
ID. You will have to enter your diets again under another unique Record ID. 
• Select Day# and Type in 1 or subsequent day number  
• Select date that diet was recorded from drop down menu 
• Select Start 
• Record food names - two-step process: 
• Type the first food item in the Diary item field. Keep it broad to start with by 
recording e.g. ‘milk’ and then the specific type/ brand. You don’t need to write 
measurements/ quantities in at this stage.  
• To select time click the up/down arrows to find the correct meal time or type the 
time in 24-hour clock format. It’s best if you record the time in at this stage. Click   
or  the ‘Return’ key between food items. Add more food items. Click the ‘Save’  
icon. 
• Click the ‘Continue diet record’  icon below the table to go to the next screen. 
• Now choose the specific foods from the Food list items to match your 
descriptions.  
• Clicking on foods in the Food item column triggers an automatic search for 
matching/close items from the Food list items (below Food diary) If a match still does 
not exist see the hints below. 
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• A food match is selected by double-clicking it. Its description is now entered into 
the diet. 
• Changes are not automatically saved - a green corner in a table cell means 
unsaved data   
• Click the ‘Save’ icon  (far left icon below the Food diary) to commit these 
changes. 
• Enter the food amounts. Click on Amount for each food and select the appropriate 
amount from the three methods available; grams; measure descriptors; volume/shape. 
NB: mls does not work on the left hand box when typing in quantities. You have 
to enter liquids on the middle box and select mls as the unit and then type in e.g. 180 



















There are two ways to create new recipes within ‘Kai-culator’;  
• New project ‘List’ recipes. This method is useful for recording generic recipes or 
for participants own recipes where they have recorded the raw ingredient 
weights or measures and then cooked the food.  
• Recording a participant’s own recipe within their diet record. This method is only 
suitable for foods which are not cooked, e.g. jelly, a sandwich or an assembly of 
Hints: The foods displayed in the Food list items can be expanded or contracted by 
changing the selection criteria in the fields ‘Starts with’ and ‘contains’ 
a) Frequently the first word is a generic name such as ‘bread’ or ‘beef’ 
b) Leave the ‘contains’ field blank to see all the options for foods that start with the 
selected name in ‘Starts with’. Add a descriptor in the ‘contains’ field to shorten 
the list to foods containing the descriptor, e.g., wholemeal or porterhouse.  
c) If ‘Starts with’ does not find the food you are looking for choose ‘Contains’ from 
the drop down list and click search. 
d) To see all of the foods in a food group click on the drop down box and select the 
food group name. Scroll up and down to familiarise yourself with foods in the 
database. (Note: leave the other fields blank) 
Hints 
a) Choose only one method for recording an amount as Kai-culator has a hierarchy of 
selection if more than one method is recorded, i.e., a value in the Measure 
descriptor ‘How many’ column takes priority over a value in the Volume ‘How 
many’ field. which takes priority over a gram value in the Amount column 
b) Click the "Save" icon  to commit these changes. 
c) If there is no density for a food a volume can not be converted to grams and so the 




already cooked ingredients, e.g. cooked pasta, pasta sauce and parmesan cheese 
topping.  
• How to create a new ‘Project’ recipe in the project 'Recipe Database': 
• Click on your project e.g. HUNT311 2018 
• Click Composition Data>Recipes 
• Click the  icon 
• Type in the name of the recipe > click ‘OK’. 
• Click the name of the recipe, then click ‘Edit recipe’  icon - new tables appear 
on the right of the screen. The top one is the recipe table. 
• In the recipe table select the cooking method from the drop down menu. 
• Type in the cooking time and temperature (100ºC for boiled, steamed, 
microwaved; 180ºC for baked, roasted, stir-fried, fried. 220ºC for grilled, 
barbecued). 
• Click 'Save' icon. 
• Record the moisture change value - see hints below. Click 'Save'  icon. 
• Add ingredients - see hints below. Click 'Save'  icon. 
• Record ingredient amounts - Click the ‘Amount’ field and record the amount as 
grams, or a measure descriptor. Click ‘OK’. Click 'Save'  icon. 
• Record the Retention factor - see hints below. Click 'Save'  icon. 
Click the 'Calculate recipe' icon and check that the nutrient values in the left hand 
right table change from '-0.1g' to a positive value. Check the water value is not zero. If it 























Hint: How to record the moisture change value 
Open a second browser, e.g., if you are already using Firefox open Chrome 
Moisture change values are found in two places in Kai-culator…  
‘Kai-culator’ recipes – within a project the ANS0809 recipes can be found in 'Composition 
Data /Recipe Database' then click the 'Switch view' icon. 
• Search for a similar recipe. Type food name in ‘Starts with’ field and click 
‘Search’. 
• Click on an appropriate recipe and click on the ‘View recipe’  icon. 
• Note the moisture factor. 
USDA moisture factors list is found in the main Kai-culator menu 
• Click 'Data' > 'Food Composition Databases' >  'Moisture factors' 
• Scroll through the long list of foods to find similar recipes and note the 
























Participants own recipes:  
The participants’ own recipes can be entered within the diet for uncooked recipes, e.g. 
smoothie, salad or sandwich or an assembled cooked food recipes, e.g. pasta and sauce if 
they have recorded the amounts of raw or cooked ingredients and the proportion of the 
recipe they consumed. If they don’t state the proportion or only state they consumed a 
weighed or measured amount such as ‘125g’ or ‘1 cup’ it might be easier to record their 
recipe as a ‘List recipe’, see above. 
How to enter a participant’s own recipe within a diet record as cooked ingredients 
and raw amounts: 
• Click ‘Food item’ cell so it turns pink > Click the recipe icon on the right 
of the same line (A new recipe screen will come up) 
• To add new ingredients Click  icon 
• Type in the name of the first ingredient  > Click OK. Click ‘Save ’  
• Type in the name of the second ingredient > Click OK repeat for all 
ingredients.  
• Click the ‘Food item’ field for the first ingredient. Check below the table to 
see if the food item you want is in the ‘Food list’, remembering to choose the 
cooked version of the food if the recipe is an assembly of cooked ingredients. 
Double click on the appropriate Food item. 
 
 
Hint: How to add ingredients 
• Click the icon. The ingredient number appears. 
• Click in the 'Food item' field which will turn pink. 
• Type the ingredient name in the ‘Starts with’ field and click 'Search'. Double 
click on the appropriate ingredient which will appear in the ‘Food item’ 
field. 
• Note: Make sure you choose raw ingredients for Project Recipes, except 
where pre-cooked items are included in a recipe. The moisture change and 
the retention factors will 'cook/convert' raw ingredient nutrient values to 
Hint: How to record the retention factor 
• Click the ‘Retention field’ for each ingredient and select the appropriate 
retention factor for the type of food and cooking method from the drop down 
menu. 
• Click ‘Save’. 
• Repeat for all ingredients. 
• Note: Some foods do not have retention factors applied e.g. sugars, fats 












• Click the ‘Amount field’. Enter the amount in the ‘g’ amount field, or choose 
a measure description or choose a volume and enter the dimensions of the 
food.  
• Repeat the last two steps for all ingredients  
• Click ‘Save recipe’           icon in the bottom left corner of the table 
• Click ‘Exit’ icon (to return to the Food Diary Reconciliation screen) 
• Click on the ‘Amount field’ > Type in % the participant consumed, e.g., 100% 
or 50% etc > Click OK 














Hints: The foods displayed in the Food list items can be expanded or 
contracted by changing the selection criteria in the fields ‘Starts with’ and 
‘contains’ 
e) Frequently the first word is a generic name such as bread or beef  
f) Leaving the ‘contains’ field blank gives all the options available 
for foods that start with the selected name in ‘Starts with’. 
Adding a descriptor in the ‘contains’ field shortens the list to 
foods containing that descriptor, e.g., wholemeal or porterhouse.  
g) If the ‘Starts with’ field does not find the food you are looking 
for choose ‘Contains’ from the drop down list and click search. 
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Appendix K: Demographic and anthropometric questionnaire 
What is your date of birth? (DD/MM/YYYY)  
 
 
Are you   female or male? (please circle) 
 
 





Weight: _________   kg                 
 
Height: __________  cm 
 










Appendix L: Exercise and intake questionnaire: glycaemic response laboratories 
ID: 
1. Did you consume any alcohol last night?  
Please circle YES / NO 
If yes how many standard drinks?  
 
2. Did you consume any beverages apart from water or food between 10am and 
12pm today?  
 Please circle YES / NO 
If yes what was it and how much? Please provide serving sizes eg medium apple, 
1 cup. 
 
3. Did you consume any beverages apart from water or food between 12 and 
2pm?  
Please circle YES / NO 
If yes what was it and how much? Please provide serving sizes eg medium apple, 
1 cup. 
 
4. Did you do any exercise apart from walking between 12 and 2pm?  
Please circle YES / NO 






Appendix M: Additional information questionnaire: satiety laboratories  
ID: 
1. Did you consume any alcohol last night?  
a. Please circle YES / NO 
b. If yes how many standard drinks?  
2. Did you consume any beverages apart from water or food between 10am and 
12pm today?  
a. Please circle YES / NO 
b. If yes what was it and how much? Please provide serving sizes eg medium 
apple, 1 cup. 
3. Did you consume any beverages apart from water or food between 12 and 
2pm?  
a. Please circle YES / NO 
b. If yes what was it and how much? Please provide serving sizes eg medium 
apple, 1 cup. 
4. Did you do any exercise apart from walking between 12 and 2pm?  
a. Please circle YES / NO 
b. If yes please describe the activity and how long you were exercising for. 		 
5. Had you seen Fat v Carbs by Jamie Owen before today? 
a. Please circle YES / NO 
b. If yes approximately how many months ago? 		 
6. Had you seen Fat vs Sugar by the van Tulleken brothers before today? 
a. Please circle YES / NO 
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b. If yes approximately how many months ago? 		 
7. Do you know which sugar was in your drink today? (please circle one) 
a. Sucrose  /  isomaltulose  /  don’t know 
 
 
 
 
 
 
 
 
 
